What can we learn from treating atopic itch in dogs? - 04/08/22
Doi : 10.1016/j.jaci.2022.05.007
Angelina Labib, BS a, Gil Yosipovitch, MD a, Thierry Olivry, DrVet, PhD b, ⁎ 
a Dr Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, Fla
b North Carolina State University College of Veterinary Medicine, Raleigh, NC
∗Corresponding author: Thierry Olivry, DrVet, PhD, North Carolina State University College of Veterinary Medicine, 1060 William Moore Dr, Raleigh, NC 27607.North Carolina State University College of Veterinary Medicine1060 William Moore DrRaleighNC27607
Key words : Atopic dermatitis, eczema, dog, pruritus, itch, JAK inhibitor, IL-31 inhibitor, oclacitinib, lokivetmab
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| Disclosure of potential conflict of interest: T. Olivry is currently a consultant of or has been recently funded by Boehringer Ingelheim Animal Health, Ceva, Dechra, Elanco, Genclis, Nextmune, Royal Canin, Virbac, and Zoetis. G. Yosipovitch has been an investigator and consultant to Galderma, Pfizer, Sanofi Regeneron, Eli Lilly, Bellus, Kiniksa, Leo, and Trevi. The remaining author states that she has no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 150 - N° 2
P. 284-286 - Agosto 2022 Ritorno al numero
Articolo precedente
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Chronic rhinosinusitis: Future treatments and unmet needs
- Sneha Giri, Alexander L. Schneider, Bruce K. Tan
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?